Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T-cell and clinical responses in melanoma stage III and IV patients
/in International Publications, Malignant Melanoma /von 2004-07-10 / Int. J. Cancer 2004 Jul;110(5):730-40Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2003-10-15 / J. Clin. Oncol. 2003 Oct;21(20):3826-35Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2003-10-01 / Melanoma Res. 2003 Oct;13(5):521-30Efficacy of superficial and deep regional hyperthermia combined with systemic chemotherapy and radiotherapy in metastatic melanoma
/in Hyperthermia, International Publications, Malignant Melanoma /von 2003-08-01 / J Dtsch Dermatol Ges 2003 Aug;1(8):635-42Intradermal injection of Newcastle disease virus-modified autologous melanoma cell lysate and interleukin-2 for adjuvant treatment of melanoma patients with resectable stage III disease
/in International Publications, Malignant Melanoma /von 2003-02-01 / J Dtsch Dermatol Ges 2003 Feb;1(2):120-5A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire
/in International Publications, Malignant Melanoma, Newcastle Disease Virus /von 1998-12-01 / Mol. Med. 1998 Dec;4(12):783-94
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de